6 February 2026·PIB

Jan Aushadhi Kendras Schemes

In this note

1. At a Glance

Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is the umbrella scheme; Jan Aushadhi Kendras (JAKs) are its dedicated retail outlets selling unbranded quality generic medicines at 50%–80% below branded MRP [1].
Run by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, via implementing agency Pharmaceuticals & Medical Devices Bureau of India (PMBI) [1][3].
Examinable as a flagship affordable healthcare / out-of-pocket expenditure reduction scheme overlapping GS-II (health governance) and GS-III (pharma sector, MSME entrepreneurship).

Janaushadhi Saptah 2026 (1–7 March 2026) — week-long outreach culminating in the 8th Janaushadhi Diwas on 7 March, with health camps at 250+ locations [3].
PIB release (6 Feb 2026) reiterated product basket of 2,110 medicines + 315 surgicals/consumables/devices and the 25,000-Kendra target by 31 March 2027 [1][2][4].

Launched in 2008 as Jan Aushadhi Campaign by Dept. of Pharmaceuticals; relaunched and rebranded as PMBJP in 2015–16 with expanded scope [1].
Implementing arm reconstituted as PMBI (earlier BPPI — Bureau of Pharma PSUs of India), a society under Dept. of Pharmaceuticals [1].
2022: Online applications invited to open Kendras in 3,579 blocks across 406 districts of 26 States/UTs [5].
16,912 JAKs operational by 30 June 2025; >18,000 by March 2026 [4][3].

Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals [1].
Implementing Agency: PMBI (Pharmaceuticals & Medical Devices Bureau of India), a registered society [3].
Portal: www.janaushadhi.gov.in [3].
Product basket: 2,110 generic medicines + 315 surgicals/consumables/devices, covering 29 therapeutic categories (cardiovascular, anti-diabetic, anti-cancer, anti-infective, anti-allergic, GI, nutraceuticals) [1][3].
Price discount: 50%–80% below branded equivalents [1].
Target: 25,000 Kendras by 31 March 2027 [4].
Eligibility to open JAK: individuals (pharmacist preferred), NGOs, societies, trusts, SHGs, hospitals, private entities [3].
Incentives: enhanced support for women, Divyang, SC/ST entrepreneurs and those in Aspirational Districts, North-East, Himalayan & Island territories [3].

Economic / Health-Financing

Targets India's high out-of-pocket expenditure (~48% of health spend; medicines the largest component) by substituting branded generics with unbranded generics at fraction price [1].
Achieved ₹1,000 cr sales milestone in FY 2023-24, signalling scale economies and reduced drug bill [5].

Social Equity

Targeted Kendras in Aspirational Districts, NE, Himalayan, Island regions correct urban-rural and regional access gaps [3].
Affirmative incentives for women/SC/ST/Divyang entrepreneurs link affordable drugs with livelihood creation [3].

Administrative / Federalism

Franchise-cum-PPP retail model; online application centrally processed by PMBI — bypasses state licensing delays [3].
Railways MoU (2023) to open PMBJKs at select railway stations — inter-ministerial expansion [6].

Scientific / Quality Assurance

All PMBJP drugs procured only from WHO-GMP & GLP-certified suppliers; tested at NABL-accredited labs before dispatch [2].

Ethical / Governance

Counters branded-generic price arbitrage and tackles physician prescription bias toward brands — links to NMC's ethical prescription guidelines.

6 Feb 2026 PIB: product basket confirmed at 2,110 + 315 items [1].
1–7 March 2026: Janaushadhi Saptah — 250+ health camps; 8th Janaushadhi Diwas on 7 March [3].
Mar 2026: Network crosses 18,000 JAKs en route to 25,000 by March 2027 [3].
30 Jun 2025: Cumulative count 16,912 JAKs [4].
2023 MoU with Ministry of Railways for station-based PMBJKs [6].

PMBJP launched (relaunched) in 2008; revamped 2015–16 [1].
Nodal Dept.: Department of Pharmaceuticals under Ministry of Chemicals & Fertilizers — NOT Ministry of Health [1].
Implementing agency: PMBI (formerly BPPI) [3].
Janaushadhi Diwas observed on 7 March annually [3].
Product basket: 2,110 medicines + 315 surgicals/devices [1].
Pricing: 50–80% cheaper than branded equivalents [1].
Target: 25,000 Kendras by 31 March 2027 [4].
16,912 JAKs by 30 June 2025; >18,000 by March 2026 [4][3].
Covers 29 therapeutic categories [3].
Special incentives in Aspirational Districts, NE, Himalayan & Island regions [3].
Application portal: janaushadhi.gov.in [3].
Crossed ₹1,000 cr in sales in FY 2023-24 [5].

GS-II: Welfare schemes for vulnerable sections; Issues relating to development and management of Health.
GS-III: Indian pharmaceutical sector; inclusive growth.
Possible stems: 1. "Jan Aushadhi Kendras have the potential to dent India's high out-of-pocket health expenditure but face acceptance and supply-chain hurdles. Examine." (GS-II) 2. "Discuss the role of generic medicines in achieving Universal Health Coverage in India, with reference to PMBJP." (GS-II) 3. "Evaluate PMBJP as a model of welfare-cum-entrepreneurship." (GS-III)

Ayushman Bharat (PM-JAY) — complementary OOP-reduction tool.
National Health Mission / NHA — health system delivery backbone.
Drugs Price Control Order (DPCO) & NPPA — price-cap regulator for essential drugs.
NLEM (National List of Essential Medicines) 2022 — overlaps with PMBJP basket.
Indian Pharmaceutical Sector / PLI for pharma & bulk drugs — supply side.
Universal Health Coverage / SDG 3 — global benchmark.
Ayushman Bharat Digital Mission (ABDM) — e-pharmacy linkages.
CDSCO & WHO-GMP standards — quality regulation backbone.

Wrong ministry: it is Chemicals & Fertilizers (Dept. of Pharmaceuticals), NOT Ministry of Health & Family Welfare.
Confusing PMBI with BPPI (BPPI was the predecessor body) or with NPPA (NPPA is a price regulator, not implementing agency).
Janaushadhi Diwas is 7 March, not 1 March (Saptah begins 1 March).
"Generic" here means unbranded generic — distinct from "branded generics" sold by Indian pharma firms.
PMBJP is not part of Ayushman Bharat; they are parallel schemes.
Number traps: 2,110 medicines + 315 surgicals (not 2,000/300); 25,000 by March 2027 (not 2025).